Protalix BioTherapeutics, Inc. (PLX) Complex Receives FDA’s Orphan Drug Designation
Earlier today, Protalix BioTherapeutics, Inc. announced exciting news regarding its proprietary plant cell, prGCD. The company has received notice from the U.S. Food and Drug Administration that the Office of Orphan Products Development has granted orphan drug designation to prGCD, which contains an expressed recombinant form of glucocerebrosidase (GCD), for the treatment of Gaucher disease. Gaucher disease is a lysosomal storage disorder resulting from a deficiency or mutation of the GCD enzyme. The disease affects the liver, spleen, bone marrow, and in some cases, the central nervous system. Orphan drug designation is granted to drugs that may potentially provide a…